FIL Limited Form 8.3 - Allergan Plc (5289M)
11 Maio 2020 - 10:18AM
UK Regulatory
TIDMTTM TIDM0Y7T
RNS Number : 5289M
FIL Limited
11 May 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing FMR LLC and/or one or more
(Note 1) of its direct or indirect
subsidiaries
And
FIL Limited and/or one
or more of its direct and
indirect subsidiaries
Company dealt in ALLERGAN PLC
==========================
Class of relevant security ORDINARY SHARES
to which the dealings
being disclosed relate
(Note 2)
==========================
Date of dealing 08-May-2020
==========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities 800,381 0.24%
================= ===================
(2) Derivatives (other
than options)
================= ===================
(3) Options and agreements
to purchase/sell
================= ===================
Total 800,381 0.24%
================= ===================
THE ABOVE INCLUDES A TRANSFER IN OF 6 ORDINARY SHARES.
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/Sale Number of relevant securities Price per unit (Note 5)
Sale 13,729 191.87 USD/Share
------------------------------ ------------------------
Sale 2,283 191.94 USD/Share
------------------------------ ------------------------
Sale 8,448 192.34 USD/Share
------------------------------ ------------------------
Sale 2,852 192.41 USD/Share
------------------------------ ------------------------
Sale 3,968 192.44 USD/Share
------------------------------ ------------------------
Sale 1,578 192.40 USD/Share
------------------------------ ------------------------
Sale 4 192.57 USD/Share
------------------------------ ------------------------
Purchase 528 192.33 USD/Share
------------------------------ ------------------------
Sale 1 192.68 USD/Share
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or
relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced.
If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 11-May-2020
Contact name Paul Clark
================
Telephone number 00353 1 223 1447
================
If a connected EFM, name
of offeree/offeror with
which connected
================
If a connected EFM, state
nature of connection (Note
10)
================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEFLFLVEDILLII
(END) Dow Jones Newswires
May 11, 2020 09:18 ET (13:18 GMT)
Allergan (LSE:0Y7T)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Allergan (LSE:0Y7T)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
